Please login to the form below

Hepatitis (C)an’t wait: taking a de-centralized approach to cure the epidemic

Hepatitis C is a curable disease, so why are so many countries off track to achieve the World Health Organization elimination target? This World Hepatitis Day, we compare several countries’ approaches to combatting the disease and explore the importance of a de-centralized strategy that overcomes the stigma preventing patients from seeking treatment.

This year’s World Hepatitis Day theme, ‘Hepatitis Can’t Wait,’ stresses the urgency of testing and treating viral hepatitis, as well as removing the stigma surrounding the disease and providing support for patients.

Treatment for hepatitis C has evolved dramatically over the past decade. The introduction of direct-acting-antivirals has revolutionized the treatment landscape, leading the World Health Organization to set a global target to eliminate the disease as a public health problem by 2030.

Today hepatitis C is a curable disease. It takes just 8–12 weeks of oral therapy to successfully cure close to 100% of patients with chronic hepatitis C virus infection. Gone are the days of thrice-weekly injections, low cure rates, and a myriad of side effects. The treatment algorithm is far simpler, the therapies are less invasive, the side effects typically milder and much less frequent, and the time patients spend taking medication is far shorter. There is limited need for pre-treatment assessments, on-treatment monitoring, and post-treatment follow-up, making it much easier for patients to fit treatment into their daily lives.

Despite huge advances in the field, the burden of hepatitis C remains a significant public health problem. The World Health Organization (WHO) estimates that 71 million people globally have chronic hepatitis C.[1] Yet, 80% are unaware of their infection status, and a significant number of those will develop cirrhosis or liver cancer if not treated.[2] So, if a cure exists, why are so many people still infected with hepatitis C virus and suffering from the consequences of ongoing chronic infection and liver damage?

Download the full article to learn about: 

  • The approaches different countries are taking to eliminating hepatitis C
  • Successful strategies for engaging hard-to-reach patients
  • Why treating patients in active addiction is crucial for tackling the disease
  • Iceland case study


31st August 2021



Company Details

Fishawack Health

+44 20 3328 1840

Contact Website

No. 3 Booths Park
Booths Hall
Chelford Road
WA16 8GS
United Kingdom

Latest content on this profile

The challenges of reimbursement and innovative pricing for cell and gene therapies
Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of innovative pricing models, including ensuring the model chosen meets the payer’s needs.
Fishawack Health
Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes
Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech giants dominate?
Fishawack Health
Fishawack Health welcomes Mario Muredda as its new President of Marketing
Fishawack Health (FH) ushers in a new era of data-driven omnichannel marketing with the hire of healthcare marketing veteran Mario Muredda.
Fishawack Health
5 ways we’re enhancing our services to support our clients in 2023
Fishawack Health CEO Jon Koch explains the new platforms, tools, and services we’re elevating to drive innovation for our clients in 2023.
Fishawack Health
Why it’s time to apply a payer lens to your early pipeline planning
Value, evidence, and market access experts Jan McKendrick and Andrea Hamlin reveal why applying a payer lens early in the value assessment of pipeline assets is essential for driving commercial success.
Fishawack Health
The fast-paced future of cell and gene therapies
In this report, we interview patients, researchers, and biopharmaceutical leaders to explore the complex landscape for the development of cell and gene therapies and share commercial recommendations from our specialist teams.
Fishawack Health